Invesco Pharmaceuticals ETF PJP
127.04 USD +0.58 (+0.46%)
Nov 6, 2026, 12:14 PM EST
126.11 Day range 127.31
96.27 52-week range 132.59
- YTD
- +21.52%
- 1 year
- +30.50%
- Market cap
- 366.94M
- EPS (ttm)
- 5.85
- P/E ratio
- 21.75
- YTD return
- +21.52%
- 1-year return
- +30.50%
- Volume
- 53.30K
- Avg volume
- 35.01K
- Open
- 126.11
- Previous close
- 126.46
- Day's range
- 126.11 – 127.31
- 52-week range
- 96.27 – 132.59
MAX +110.90 (+712.72%)
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 86.39
- 200-day average
- 83.44
About Invesco Pharmaceuticals ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
News
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)? 
What's Going On With Amgen Stock Tuesday? 
Two Years to Build or Pay 200% — Which US Pharma Stocks Win? 
Amgen Posts 77% Response In Thyroid Eye Disease Study 
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial 
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' 
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' 
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms 
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing 
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
Your note
Sign in to keep a note on PJP — it syncs with the Stock Master app.